bioAffinity Technologies Announces Board and Executive Changes
Ticker: BIAFW · Form: 8-K · Filed: Aug 18, 2025 · CIK: 1712762
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
Related Tickers: BIAF
TL;DR
Board shakeup and exec comp changes at BIAF - filing details new directors and pay structures.
AI Summary
bioAffinity Technologies, Inc. announced on August 12, 2025, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. This report also includes financial statements and exhibits related to these corporate governance and compensation matters.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, operational focus, or financial priorities, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding future strategy and execution.
Key Numbers
- 001-41463 — SEC File Number (Identifies the company's filing with the SEC.)
- 46-5211056 — EIN (Company's Employer Identification Number.)
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- August 12, 2025 (date) — Earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-41463 (commission_file_number) — SEC File Number
- 46-5211056 (ein) — I.R.S. Employer Identification Number
FAQ
What specific roles have been affected by the departure of officers or directors?
The filing indicates the departure of certain officers and directors, but does not specify the exact roles in the provided text.
Who are the newly elected directors?
The filing mentions the election of new directors but does not name them in the provided text.
What are the key changes in the compensatory arrangements for certain officers?
The filing states that there are updates to compensatory arrangements for certain officers, but the specifics are not detailed in the provided text.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is August 12, 2025.
What is the primary business of bioAffinity Technologies, Inc. according to the filing?
bioAffinity Technologies, Inc. is in the business of SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731].
Filing Stats: 711 words · 3 min read · ~2 pages · Grade level 9.7 · Accepted 2025-08-18 16:15:54
Filing Documents
- form8-k.htm (8-K) — 45KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-1_001.jpg (GRAPHIC) — 28KB
- 0001641172-25-024614.txt ( ) — 309KB
- biaf-20250812.xsd (EX-101.SCH) — 4KB
- biaf-20250812_def.xml (EX-101.DEF) — 26KB
- biaf-20250812_lab.xml (EX-101.LAB) — 36KB
- biaf-20250812_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 18, 2025 BIOAFFINITY TECHNOLOGIES, INC. (Registrant) By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-